OBIO (Orchestra BioMed Holdings) Total Inventories: $0.25 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OBIO Orchestra BioMed Holdings Inc OBIO
42 GF Score
Price $5.81
GF Value $31.57
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Orchestra BioMed Holdings Total Inventories?

Orchestra BioMed Holdings OBIO +7.00% 42 Total Inventories is $0.25 Mil as of Jun. 2026. GuruFocus rates OBIO with a GF Score™ of 42/100 and a GF Value™ of $31.57 (Possible Value Trap). The stock has 6 warning signs investors should review.

Orchestra BioMed Holdings's total inventories for the quarter that ended in Jun. 2026 was $0.25 Mil. Orchestra BioMed Holdings's average total inventories from the quarter that ended in Mar. 2026 to the quarter that ended in Jun. 2026 was $0.26 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Orchestra BioMed Holdings's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was $0.23.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Orchestra BioMed Holdings's Days Inventory for the three months ended in Jun. 2026 was 961.78.

Inventory Turnover measures how fast the company turns over its inventory within a year. Orchestra BioMed Holdings's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.09.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Orchestra BioMed Holdings's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 2.99.


Orchestra BioMed Holdings  (NAS:OBIO) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Orchestra BioMed Holdings's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is

Net-Net Working Capital Per Share (Q: Jun. 2026 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(109.963+0.75 * 0.051+0.5 * 0.25-96.377
-0-0)/60.105
=0.23

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Orchestra BioMed Holdings's Days Inventory for the three months ended in Jun. 2026 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2026 )/Cost of Goods Sold (Q: Jun. 2026 )*Days in Period
=0.2635/0.025*365 / 4
=961.78

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Orchestra BioMed Holdings's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2026 ) / Average Total Inventories (Q: Jun. 2026 )
=0.025 / 0.2635
=0.09

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Orchestra BioMed Holdings's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2026 ) / Revenue (Q: Jun. 2026 )
=0.2635 / 0.088
=2.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Orchestra BioMed Holdings Total Inventories Related Terms


Orchestra BioMed Holdings Total Inventories Historical Data

* Premium members only.

The historical data trend for Orchestra BioMed Holdings's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orchestra BioMed Holdings Total Inventories Chart

Orchestra BioMed Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Inventories
Get a 7-Day Free Trial 0.07 0.28 0.15 0.17 0.31

Orchestra BioMed Holdings Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.37 0.31 0.28 0.25
OBIO
42GF Score
Orchestra BioMed Holdings Inc OBIO
Total Inventories is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orchestra BioMed Holdings Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of $0.25 Mil mean?
Orchestra BioMed Holdings (OBIO) has a Total Inventories of $0.25 Mil as of Jun. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Orchestra BioMed Holdings and its competitors.
Is Orchestra BioMed Holdings' Total Inventories too high?
Orchestra BioMed Holdings' current Total Inventories is $0.25 Mil. Overall, Orchestra BioMed Holdings has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Orchestra BioMed Holdings' Total Inventories compare to CYDY and IRD?
Orchestra BioMed Holdings' Total Inventories of $0.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Orchestra BioMed Holdings and its competitors. Orchestra BioMed Holdings's current Total Inventories is $0.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchestra BioMed Holdings stock overvalued right now?
Based on GuruFocus' analysis, Orchestra BioMed Holdings (OBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $31.57, compared to a current price of $5.81 — trading 81.6% below its estimated fair value. The current Total Inventories is $0.25 Mil. Orchestra BioMed Holdings' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Orchestra BioMed Holdings (OBIO), the current Total Inventories is $0.25 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orchestra BioMed Holdings (OBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Orchestra BioMed Holdings stock appears to be undervalued. The current stock price of $5.81 is trading 81.6% below its estimated GF Value™ of $31.57. GuruFocus considers Orchestra BioMed Holdings to be Possible Value Trap.

Key valuation signals for OBIO:

  • Total Inventories: $0.25 Mil
  • GF Value™: $31.57 vs. price of $5.81 (81.6% below fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the OBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orchestra BioMed Holdings Business Description

Address 150 Union Square Drive, New Hope, PA, USA, 18938
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
42GF Score

Get the complete analysis for OBIO

Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.81
Price
$31.57
GF Value